According to industry statistics, since the beginning of 2022, 270 companies have implemented fixed increases, with a total amount of 532.
123 billion yuan
.
Among them, there are 10 companies with an additional issuance amount of more than 10 billion yuan, 11 companies with an additional issuance amount of 5 billion yuan ~ 10 billion yuan, 50 companies with an additional issuance amount of 2 billion yuan ~ 5 billion yuan, 48 companies with an additional issuance amount of 1 billion yuan ~ 2 billion yuan, 151 companies with an additional issuance amount of less than 1 billion yuan, and 87 companies with an additional issuance of less than 500 million yuan
.
From the perspective of the enterprises with the highest amount of funds raised during the year, they are mainly concentrated in power equipment, transportation, electronics, medicine and biology industries
.
Among them, in the pharmaceutical industry, there are 3 pharmaceutical companies with additional funds of more than 3.
5 billion yuan, namely Shanghai Pharmaceutical, Fosun Pharma and Aier Ophthalmology
.
Shanghai Pharmaceutical: The total amount of funds raised during the year exceeded 10 billion yuan
Specifically, Shanghai Pharmaceutical completed a fixed increase project with a total fundraising of 13.
975 billion yuan during the year, introduced Yunnan Baiyao as a strategic investor, issued about 666 million A shares to it privately, and subscribed 10.
91 billion yuan
to Yunnan Baiyao.
At the same time, about 187 million shares were issued to Shanghai Tandong Enterprise Consulting Services Co.
, Ltd.
, a wholly-owned subsidiary of Shanghai SIIC, the company's controlling shareholder, and 3.
065 billion yuan
was subscribed by Shanghai Tandong He.
Industry analysts pointed out that Shanghai Pharmaceutical's reintroduction of Yunnan Baiyao can be said to be a strong alliance, and the company is expected to usher in a new reform bureau from system innovation to business innovation in the future
.
Shanghai Pharmaceutical said that all the net funds raised will be used to supplement working capital and repay the company's debts, of which 3 billion yuan will be used to repay the company's debts and the remaining part will be used to supplement working capital
.
The company's first three quarterly reports show that the company achieved operating income of 174.
073 billion yuan from January 1, 2022 to September 30, 2022, a year-on-year increase of 8.
46%, net profit attributable to the parent company of 4.
814 billion yuan, a year-on-year increase of 7.
35%, and basic earnings per share of 1.
45 yuan
.
Fosun Pharma: The total amount raised during the year was approximately RMB4.
484 billion
Fosun Pharma and Fosun International jointly announced on July 20 that Fosun Pharma issued a total of 106 million new A shares to 10 investors at a price of 42 yuan per share, raising a total of about 4.
484 billion yuan
.
The non-public offering of A-shares constitutes a sale of Fosun Pharma's equity interest
in Fosun International held by Fosun International.
It is understood that a total of 10 institutions participated in Fosun Pharma's additional issuance, including Shanghai Gaoyi Asset Management Partnership (Limited Partnership)-Gaoyi Linshan No.
1 Yuanwang Fund (hereinafter referred to as Gaoyi Asset) with a capital of about 2 billion yuan, and UBS AG, Caitong Fund Management Co.
, Ltd.
, Guotai Junan Asset Management (Asia) Co.
, Ltd.
, J.
P Morgan, Huatai Securities Co.
, Ltd.
, etc
.
According to the financial report, Fosun Pharma achieved revenue of 31.
6 billion yuan in the first three quarters of 2022, a year-on-year increase of 16.
87%; net profit was 2.
454 billion, down 31.
15% year-on-year; Net profit after deduction was 2.
859 billion yuan, a year-on-year increase of 15.
51%.
Aier Ophthalmology: A total of approximately RMB3,536 million was raised during the year
Aier Eye released the results of the fixed increase on November 11, showing that the number of shares issued was about 133 million shares at a price of 26.
49 yuan per share, raising a total of about 3.
536 billion yuan
.
Among them, ICBC Credit Suisse Fund received a relatively high number of allotted shares, with an allotted amount of 630 million yuan, in addition to the participation
of large domestic and foreign institutions such as GF Fund, UBS Group and JPMorgan Chase Securities.
According to the third quarter report of 2022, the company achieved operating income of 13.
052 billion yuan in the first three quarters, a year-on-year increase of 12.
55%, and a net profit attributable to the parent of 2.
357 billion yuan, a year-on-year increase of 17.
65%.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
